Siebe. Profile picture
🎯 Goal: Clinical Trial Abundance for Infection-Associated Chronic Illnesses | MA Philosophy | MSc Business | ❤️ nuance | effective altruism

Aug 2, 2023, 12 tweets

UCSF, led by @MichaelPelusoMD, is starting this trial with the anti -SARS-CoV-2 spike antibody cocktail AER002.


Why I'm so excited that this can cure viral persistence in Long Covid:classic.clinicaltrials.gov/ct2/show/NCT05…

- AER002 is probably the two mAbs P2G3 LS & P5C3 LS derived from a human, which the inventors of Aerium Therapeutics describe in their paper: ncbi.nlm.nih.gov/pmc/articles/P…

- It has strong neutralization against all SARS-CoV-2 tested (up to BA.5) ➡️ matches the persistent viral stains

Both mAbs have Antibody-Dependent Cellular Cytotoxicity (ADCC) & AD Cellu Phagocytosis (ADCP):

mAbs bind to the spikes that are left on the surface of the infected cells and their Fc regions (their tails) act as receptors for NK cells & phagocytes to kill & eat infected cells.

That is: they can completely clear out a viral infection, even if there is no detectable viral replication. This circumvents SARS-CoV-2's immune evasion.

PwLC were found to have impaired Antibody-dependent NK cell activation, but not ADCP. medrxiv.org/content/10.110…

The antibodies contain the LS mutation in the Fc region, which appears to confer a half-life on the order of months.

So there's a scenario where it helps to suppress but not fully clear the infection, where you get an infusion 2 or 3 times a year.

The two mAbs given together would also increase the threshold for the virus to develop resistance.

The authors state that the antibodies have good effectiveness against mutations that would escape one or the other.

Downsides:
➡️ Needs IV
➡️ Anecdotally, mAbs sometimes cause inflammation, especially with ADCC. This needs to be managed clinically to prevent collateral damage but not stop the immune system working.
➡️ Can't reach the brain
➡️ If neurons are infected, maar nog want to kill them

They are trialing it in 20 people, with 10 controls with what seems like a pretty high dose (1200mg)

Most other mAbs have very limited ADCC, except for Sotrovimab

CD16 activation is a proxy for ADCC here
ncbi.nlm.nih.gov/pmc/articles/P…

Correction: looks like AER002 only refers to P2G3? (The one with more ADCC & active against BA5, but weaker neutralisation overal)


Not entirely clear thoughlinkedin.com/posts/prakash-…

@threadreaderapp unroll please

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling